Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 5, 2026

Stock market today: Dow falls more than 900 points, S&P 500 and Nasdaq slide as Iran war jitters return with another oil surge

View original at finance.yahoo.com
Stock market today: Dow falls more than 900 points, S&P 500 and Nasdaq slide as Iran war jitters return with another oil surge US stocks ground lower on Thursday as Wall Street failed to build on a rebound session, with conflict in the Middle East holding focus amid a renewed surge in oil prices…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We decided to take this more bold, upfront, decisive action so that we could rebuild and move forward from here, versus continuously being reactive and death by a thousand cuts over the next couple of years

    80% confidence
  • Broadcom achieved record first quarter revenue on continued strength in AI semiconductor solutions. Q1 AI revenue of $8.4 billion grew 106% year over year, above forecast, driven by robust demand for custom AI accelerators and AI networking

    80% confidence
  • 75% of Cash App's customer service questions and answers are handled through automation, and oftentimes these agents actually get a customer to their answer faster with strong NPS and CSAT scores

    80% confidence
  • I already have some shares, but the goal was to continue to demonstrate alignment with shareholders. As CEO, I absolutely believe in Berkshire. I inherited a company that has an incredible foundation

    80% confidence
  • The US is doing very well on the war front

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com